The investigational ALK inhibitor lorlatinib, whose early clinical activity was first reported last year, continues to look promising in advanced ALK-positive or ROS1-positive non–small cell lung cancer. In a phase II study, robust responses were seen in previously untreated patients, as well as those who had received as many as three prior ALK inhibitors.

中文翻译：

---

非小细胞肺癌中的洛拉替尼：疗效稳定

研究性ALK抑制剂lorlatinib的早期临床活性是去年首次报道的，在晚期ALK阳性或ROS1阳性的非小细胞肺癌中，其应用前景仍然看好。在一项II期研究中，在先前未治疗的患者以及之前接受过多达三种ALK抑制剂的患者中均观察到了强烈的反应。